Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 7/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823437 | 1.00 | FFAR1 (0.51) | FFAR1LMNAHPGDEEF2KGAA | |
| SCHEMBL16823438 | 1.00 | FFAR1 (0.51) | FFAR1LMNAHPGDEEF2KGAA | |
| SCHEMBL22088585 | 0.90 | CES2 (0.45) | FFAR1EEF2KCTSA | |
| SCHEMBL68253 | 0.90 | FFAR1 (0.58) | FFAR1LMNAHPGDGAACACNA2D1 | |
| SCHEMBL3548212 | 0.89 | FFAR1 (0.46) | FFAR1EEF2KCTSACYP3A4CYP2C9 | |
| SCHEMBL4451028 | 0.89 | EEF2K (0.54) | FFAR1EEF2KCTSACACNA2D1CACNA1B | |
| SCHEMBL22089315 | 0.88 | GABBR2 (0.50) | FFAR1LMNAEEF2KCTSAMEN1 | |
| SCHEMBL16430987 | 0.86 | CYP2C19 (0.41) | FFAR1LMNAHPGDGAACACNA2D1 | |
| SCHEMBL6703313 | 0.85 | CACNA2D1 (0.55) | FFAR1LMNAHPGDEEF2KGAA | |
| SCHEMBL16853745 | 0.85 | CACNA2D1 (0.55) | FFAR1LMNAHPGDEEF2KGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027593-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3113780-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| US-9994587-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9737545-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737545-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| CN-104755475-A | Hiv protease inhibitors | MERCK SHARP & DOHME | 2015-07-01 | — | — | CN | disclosed |
| WO-2015095265-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015017393-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015013835-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015013835-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017393-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | PREP, CTSZ, PEPD | FFAR1 3503/4885LMNA 3056/4885HPGD 541/4885 |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | FFAR1 4488/4885LMNA 2669/4885HPGD 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.